AstraZeneca Says Farxiga Heart Treatment Phase 3 Trial Met Primary Endpoint
05 Mai 2022 - 8:57AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Thursday that its Farxiga drug showed
positive results from the Deliver and Dapa-HF Phase 3 trial in
reducing the risk of cardiovascular death or worsening heart
failure.
The Anglo-Swedish pharma giant said that the trial was conducted
in patients suffering from heart failures with mildly reduced or
preserved ejection fraction.
"The safety and tolerability profile of Farxiga in the Deliver
Phase 3 trial were consistent with the well-established safety
profile of the medicine," it added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 05, 2022 02:42 ET (06:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
